Tech Buzz <> Med-X

August 07, 2025

Tech Buzzer,

We’ve got another pre-IPO offering for you, from a company advancing humanity from a health perspective. Check out the deal and deal page if it’s a fit for your portfolio.

Nature-Cide Is Winning the War on Pesticides

Back the Med-X team reshaping global pest control — and join a mission that matters. Reserved Nasdaq ticker MXRX, pre-IPO shares are available.

Toxic pesticides are everywhere — in our homes, on our crops, and in our air. They're linked to chronic disease, crop loss, and vector-borne diseases like West Nile and dengue. Yet for decades, there’s been no better option.

Med-X, Inc. is changing that with Nature-Cide — a scientifically proven, plant-based pesticide brand trusted by pros around the world. Made with essential oils like clove, cedar, and cottonseed, it’s already being used in homes, hospitals, agriculture, and aerial mosquito control programs.

We started Nature-Cide to protect people, pets, and the planet — and now we’re giving everyday investors the chance to own a piece of that mission. This isn’t just about business growth. It’s about replacing toxic pesticides with safer solutions, globally.

Matthew Mills, Co-Founder & CEO of Med-X

Global Reach. Local Impact.

  • Trusted by top pest control companies around the globe

  • Deployed via aerial applications by public health departments

  • Available online through Amazon, Walmart, Kroger, and more

  • OMRI certified for use in organic food production

  • Gaining traction with state and federal governments for post-disaster relief and vector control

Why Invest in Med-X Now?

  • Rapidly growing biopesticide market: projected $17.6B by 2030

  • Proven product-market fit with $6.4M in sales in the last 4 years

  • NASDAQ symbol reserved MXRX as Med-X prepares for Direct-Listing

  • Launching new products like rodent repellents and insecticidal soil

  • Expanding into 41+ markets including South America, Asia, Australia and the Middle East

This is your opportunity to get in early and own equity in a company redefining public health, agriculture, and the environment — all at once.

Med-X is now offering shares through a Reg. A+ capital raise at $4.00 per share before their planned Nasdaq listing.

Disclaimer - This is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at https://invest.medx-rx.com/